
- /
- Supported exchanges
- / US
- / ADIL.NASDAQ
Adial Pharmaceuticals Inc (ADIL NASDAQ) stock market data APIs
Adial Pharmaceuticals Inc Financial Data Overview
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Adial Pharmaceuticals Inc data using free add-ons & libraries
Get Adial Pharmaceuticals Inc Fundamental Data
Adial Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -8 706 163
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.495
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adial Pharmaceuticals Inc News

Adial Pharmaceuticals files patent update for alcohol disorder treatment
GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a micro-cap pharmaceutical company with a market capitalization of $5 million, announced on Wednesday it has filed an update to its provisi...


Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck
Company Logo The global alcohol use disorder market is experiencing significant growth, driven by increasing demand for innovative and personalized treatments, and the integration of digital health t...

VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
(RTTNews) - What's driving the momentum in the following stocks? Vor Bio, Inc. (VOR) has secured ex-Greater China rights from RemeGen Co., Ltd. to develop and commercialize Telitacicept, a novel dual...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.